NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board

NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's
Pharmaceutical Group, to Board 


FLEMINGTON, N.J., March 1  /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. 
(BULLETIN BOARD: NVDL)  has named Robert G. Savage, former worldwidechairman of
Johnson & Johnson's Pharmaceutical Group, to its board of directors.

Mr. Savage has been a top pharmaceutical executive for almost 20 years. As
worldwide chairman of the Pharmaceuticals Group at J & J, he managed a business
with annual netsales of more than $13 billion and 33,000 employees and was both
a company officer and a member of the executive committee.

At J & J, Mr. Savage led the acquisition and integration of Alza
Pharmaceuticals, the largest and most aggressive of J & J's acquisitions to
date. He also served J & J in the capacity of company group chairman and
president of Ortho-McNeil Pharmaceuticals.

Most recently, Mr. Savage was president for the General Therapeutics and
Inflammation Business for Pharmacia Corporation where he held global
responsibility for the inflammation portfolio.  He has held multiple positions
at Hoffmann-La Roche and Sterling Drug, leading marketing, business development
and strategic planning.

"Bob's desire to join NovaDel's board is a tremendous vote of confidence for our
science and business strategy," said Gary A. Shangold, MD, NovaDel's CEO.  "The
depth and breadth of his experience will add significant strength to our
planning and execution."

Mr. Savage serves as a director for Noven Pharmaceuticals, a leader in the
development of advanced drug delivery technologies; The Medicines Company, a
pharmaceutical company focusing on the development and marketing of products
that improve specialized care; and Vela Pharmaceuticals, a specialty pharma
company focusing on pre-clinical research and clinical development. Mr. Savage
received a BS in biology from Upsala College and an MBA from Rutgers
University.

About NovaDel Pharma Inc.

NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the
development of novel drug delivery systems for prescription and over-the-
counter drugs.  The Company's proprietary lingual spray technology delivery
system offers the patient (i) fast onset of action; (ii) improved drug safety by
reducing the required drug dosage and reducing side effects; (iii) improved
patient convenience and compliance; and (iv) enhanced dosage reliability.  The
Company plans to develop such products independently and through collaborative
arrangements with majorpharmaceutical and biotech companies.

Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve known and unknown risks
and uncertainties that may cause the Company's actual results or outcomes to be
materially different from those anticipated and discussed herein including, but
not limited to, the ability to develop products (independently and through
collaborative arrangements), and the ability to commercialize and obtain
approval for products under development. Further, the Company operates in
industries where securities may be volatile and may be influenced by regulatory
and other factors beyond the Company's control. Important factors that the
Company believes might cause such differences are discussed in the risk factors
detailed in the Company's most recent Annual Report and Registration Statements,
filed with the Securities and Exchange Commission.  In assessing forward-looking
statements contained herein, if any, the reader is urged to carefully read all
cautionary statements contained in such filings.

   Contact:
   Barry C. Cohen                            Thomas Redington
   VP Business &New Product Development     203 222-7399
   908 782-3431 x 2160                       212 926-1733
   NovaDel Pharma Inc.                       

DATASOURCE: NovaDel Pharma Inc.



CONTACT:  Barry C. Cohen, VP Business & New Product Development of

NovaDel Pharma Inc., [phone] ext. 2160; or Thomas Redington of

Redington, Inc., [phone], [phone], or

Copyright